Remus Pharmaceuticals share news, announcements and annual reports
NSE: REMUSPharmaceuticals & Biotechnology
Remus Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2023 · Issue price ₹1,229
Last close ₹843.35down ₹30.45 (3.48%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹873.80.
30 Oct: open ₹855.00, high ₹855.00, low ₹830.10
52-week range of traded prices to 30 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results, dividend and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹994 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.83
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,70066.7% delivered
Remus Pharmaceuticals board meetings
25 filed, newest first.
Oct 2026
Jun 2026
23 Jun · Board meeting
May 2026
Nov 2025
Aug 2025
29 Aug · Board meeting
Jul 2025
7 Jul · Board meeting
Jun 2025
20 Jun · Board meeting
May 2025
17 May · Board meeting
Feb 2025
27 Feb · Board meeting
Nov 2024
Aug 2024
14 Aug · Board meeting
May 2024
16 May · Board meeting
Apr 2024
23 Apr · Board meeting
18 Apr · Board meeting
Meeting on 23 Apr 2024: “REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Apr-2024 to consider and approve Dividend/Bonus/Increase in authorised capital/Other business.”16 Apr · Board meeting
Not held on this date
Feb 2024
14 Feb · Board meeting
7 Feb · Board meeting
Dec 2023
28 Dec · Board meeting
Oct 2023
Sep 2023
15 Sep · Board meeting
Aug 2023
4 Aug · Board meeting
May 2023
30 May · Board meeting